Sitazit (Sitagliptin Hydrochloride)

Sitagliptin is an oral antidiabetic medication belonging to the DPP‑4 inhibitor class, widely used to improve blood glucose control in patients with type 2 diabetes. By blocking the DPP‑4 enzyme, sitagliptin increases levels of incretin hormones that stimulate insulin release and reduce glucagon secretion when blood glucose levels are elevated. This glucose‑dependent mechanism makes sitagliptin a well‑tolerated option with a low risk of hypoglycemia, especially when not combined with sulfonylureas or insulin. Sitagliptin is commonly used as monotherapy when metformin is not tolerated, or as part of combination therapy with metformin, SGLT2 inhibitors, or insulin for enhanced glycemic control. It is weight‑neutral, convenient to take once daily, and widely recommended in diabetes management guidelines as an add‑on therapy for patients needing improved HbA1c control.